Rapid genetic selection of inhibitor-resistant protease mutants: Clinically relevant and novel mutants of the HIV protease

AIDS Research and Human Retroviruses

Volumn 17, Issue 13, 2001, Pages 1249-1255

  Sices, Harry J ^a   Leusink, Mary D ^a   Pacheco, Alonso ^a   Kristie, Thomas M ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INDINAVIR; NELFINAVIR; PROTEINASE; PROTEINASE INHIBITOR; SAQUINAVIR;

ARTICLE; BACTERIOPHAGE; ENZYME INHIBITION; GENETIC SELECTION; NONHUMAN; PRIORITY JOURNAL; VIRUS ISOLATION; VIRUS MUTANT; VIRUS MUTATION; VIRUS RESISTANCE;

BACTERIOPHAGE LAMBDA; CLONING, MOLECULAR; DRUG RESISTANCE, VIRAL; HIV; HIV PROTEASE; HIV PROTEASE INHIBITORS; MUTATION; SELECTION (GENETICS);

EID: 0034803383     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/088922201750461302     Document Type: Article

References (22)

1. Regulated intramembrane proteolysis: A control mechanism conserved from bacteria to humans
2. Cellular mechanisms of beta-amyloid production and secretion
3. Beta-secretase cleavage of Alzheimer’s amyloid precursor protein by the transmembrane aspartic protease BACE
4. A presenilin-1-dependent gamma-secretase-like protease mediates release of Notch intracellular domain
5. Presenilin is required for activity and nuclear access of Notch in Drosophila
6. Caspases: The proteases of the apoptotic pathway
7. Caspases: Intracellular signalling by proteolysis
8. Rational design of peptide-based HIV proteinase inhibitors
9. Structure-based inhibitors of HIV-1 protease
10. In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors
11. HIV protease genotype and viral sensitivity to HIV protease inhibitors following saquinavir therapy
12. In vivo selection of HIV-1 variants with reduced susceptibility to the protease inhibitor L-735, 524 and related compounds
13. Structural mechanisms of HIV drug resistance
14. Ordered accumulation of mutations in HIV protease confers resistance to ritonavir
15. Non-active site changes elicit broad-based cross-resistance of the HIV-1 protease to inhibitors
16. Development of drug resistance to HIV-1 protease inhibitors
17. Identification of biased amino acid substitution patterns in human immunodeficiency virus type 1 isolates from patients treated with protease inhibitors
18. A genetic screen for the isolation and characterization of site-specific proteases
19. Isolation of new ribozymes from a large pool of random sequences
20. Kinetic characterization and cross-resistance patterns of HIV-1 protease mutants selected under drug pressure
21. DNA shuffling by random fragmentation and re-assembly: In vitro recombination for molecular evolution
22. Structure of a non-peptide inhibitor complexed with HIV-1 protease. Developing a cycle of structure-based drug design